PURE Bioscience (PURE) Downgraded by ValuEngine

ValuEngine lowered shares of PURE Bioscience (OTCMKTS:PURE) from a hold rating to a sell rating in a report issued on Friday.

PURE Bioscience (OTCMKTS:PURE) opened at $1.00 on Friday. PURE Bioscience has a 1 year low of $0.75 and a 1 year high of $1.36.

WARNING: “PURE Bioscience (PURE) Downgraded by ValuEngine” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/11/13/pure-bioscience-pure-downgraded-by-valuengine.html.

About PURE Bioscience

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply